NASDAQ:TROV - TrovaGene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.37 0.00 (0.00 %)
(As of 04/21/2019 02:20 AM ET)
Previous Close$3.37
Today's Range$3.30 - $3.45
52-Week Range$2.52 - $25.20
Volume101,382 shs
Average Volume880,216 shs
Market Capitalization$13.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380,000.00
Book Value$2.63 per share

Profitability

Net Income$-16,460,000.00
Net Margins-4,354.76%

Miscellaneous

EmployeesN/A
Market Cap$13.55 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

When did TrovaGene's stock split? How did TrovaGene's stock split work?

Shares of TrovaGene reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) issued its earnings results on Wednesday, March, 6th. The medical research company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.05. The medical research company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.08 million. TrovaGene had a negative net margin of 4,354.76% and a negative return on equity of 142.49%. View TrovaGene's Earnings History.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for TrovaGene.

What price target have analysts set for TROV?

3 Wall Street analysts have issued 12-month price targets for TrovaGene's stock. Their predictions range from $8.00 to $42.00. On average, they anticipate TrovaGene's stock price to reach $23.3333 in the next year. This suggests a possible upside of 592.4% from the stock's current price. View Analyst Price Targets for TrovaGene.

What is the consensus analysts' recommendation for TrovaGene?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (3/12/2019)
  • 2. Maxim Group analysts commented, "Trovagene reported 2Q18 with a net loss of $6.5M and ended the period with $18.5M in cash on the balance sheet. With operating expenses of $4.5M, which we estimate should rise as clinical programs around PCM-075 advance, Trovagene has runway into mid-2019." (8/6/2018)

Has TrovaGene been receiving favorable news coverage?

Media coverage about TROV stock has been trending positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TrovaGene earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TrovaGene investors own include XOMA (XOMA), Alibaba Group (BABA), Idera Pharmaceuticals (IDRA), Micron Technology (MU), Alnylam Pharmaceuticals (ALNY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL) and MannKind (MNKD).

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $3.37.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $13.55 million and generates $380,000.00 in revenue each year. The medical research company earns $-16,460,000.00 in net income (profit) each year or ($8.26) on an earnings per share basis.

What is TrovaGene's official website?

The official website for TrovaGene is http://www.trovagene.com.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  526
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel